Can Rituximab Change the Usually Dismal Prognosis of Patients With Intravascular Large B-Cell Lymphoma?
- 1 November 2008
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (31), 5134-5136
- https://doi.org/10.1200/jco.2008.19.1841
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in JapanJournal of Clinical Oncology, 2008
- Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus MeetingJournal of Clinical Oncology, 2007
- Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regionsHaematologica, 2007
- Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’1British Journal of Haematology, 2004
- Anthracycline-based chemotherapy as primary treatment for intravascular lymphomaAnnals of Oncology, 2004
- Intravascular large B‐cell lymphoma presenting with mass lesions in the central nervous system: A report of five casesPathology International, 2004
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 2002
- An Asian Variant of Intravascular Lymphomatosis: An Updated Review of Malignant Histiocytosis-Like B-Cell LymphomaLeukemia & Lymphoma, 1999